Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888037 | 1.00 | EPHX2 (0.46) | EPHX2NPC1RAB9AEPHX1LMNA | |
| SCHEMBL4889350 | 0.93 | EPHX2 (0.47) | EPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL4603422 | 0.93 | EPHX2 (0.47) | EPHX2NPC1RAB9AEPHX1 | |
| SCHEMBL4880576 | 0.92 | EPHX2 (0.53) | EPHX2 | |
| SCHEMBL2790679 | 0.90 | MMP1 (0.39) | — | |
| SCHEMBL2790678 | 0.90 | MMP1 (0.39) | — | |
| SCHEMBL4603007 | 0.90 | NPC1 (0.41) | NPC1RAB9ALMNA | |
| SCHEMBL4616166 | 0.87 | EPHX2 (0.45) | EPHX2NPC1RAB9AEPHX1LMNA | |
| SCHEMBL4616167 | 0.87 | EPHX2 (0.45) | EPHX2NPC1RAB9AEPHX1LMNA | |
| SCHEMBL4616169 | 0.87 | EPHX2 (0.45) | EPHX2NPC1RAB9AEPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
| WO-2006115353-A9 | A NOVEL HYDROXAMIC ACID DERIVATIVE AS PEPTIDE DEFORMYLASE INHIBITOR AND MANUFACTURING METHOD THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | EPHX2 2553/4885NPC1 2506/4885RAB9A 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.